A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

May 20, 2008

New HIV Drug Discovery

In their discovery of a new way to inhibit formation of HIV’s protease enzyme, scientists may have identified a new drug target, according to new data published in the August 2008 issue of Biopolymers and reported today by ScienceDaily.

Protease is a doughnut-shaped enzyme involved in processing viral proteins and assembling them into new infectious viruses. It is currently the target of a handful of drugs called protease inhibitors, all of which bind to and block the hole in the doughnut shape.

Heather Carlson, PhD, a professor of chemistry at the University of Michigan, and her colleagues used computer models of the protease enzyme to discover a new part of the enzyme’s structure that would be vulnerable to chemical inhibition. They found that before the protease assumes its doughnut shape, two ends have to bind together to close the circle. Where these two flaps join is the site that Carlson’s team chose to focus on.

Using their computer models, they developed a chemical inhibitor that was successful at stopping the two ends from joining and the enzyme from maturing into its final shape. The chemical inhibitor they developed is too weak to work as a drug in the human body, but Carlson’s discovery does offer a potential new target for drug development.

Search: Heather Carlson, University of Michigan, Biopolymers, protease


Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 3 (of 3 total)    

Sean Cruz, , 2009-04-07 00:42:52
The above statement is seen to be contradictory. The situation is very critical and need an experience complainer to resolve it. Sean Cruz

pablo, Newport Beach, CA, 2008-06-16 09:46:23
A CURE... A medium to STOP the virus. A Key to disrupting and ultimatelly destroying the virus and render it useless. THAT is what we mostly need. We crave the news of such discovery to be done ASAP. Yes Current drugs are life savers and all but we know little about the long term side effects of such chemicals. Even today, under the "best" prescription of drug treatments. We don't know the long time effects of these. A CURE is desperatelly needed. not another drug...

Nate HJohnson, Cincinnati, 2008-05-21 11:37:37
As a consumer of protease inhibitors since 2 days after their widespread release I have great interest in this new development. I am a member of the AIDS Clinical Trials national consumer board the NCAB and have a keen interest in development of new and less toxic drugs to fight, or erradicate HIV. This is exciting news!

comments 1 - 3 (of 3 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    aqua_31206
    Macon
    Georgia


    tomben56
    folsom
    California


    latinblu42
    bronx
    New York


    posattitude2011
    Williamstown,NJ
    New Jersey
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.